Loading stock data…
biote Corp (BTMD)
$1.67-0.12 (-6.70%)
After Hours$1.70+0.03 (+1.80%)· Last close Jun 29
biote Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
biote Corp. in the Healthcare sector is trading at $1.67 with a market capitalization of $78M. Wall Street consensus targets $2.99 (5 analysts), implying a +78.8% move over the next 12 months. The stock is currently near its 52-week low of $1.27, remaining 28.6% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +78.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 25) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $44.94M↓ | $46.41M↓ | $47.96M↓ | $48.86M↓ | $48.99M |
| Gross Profit | $30.95M↓ | $31.57M↓ | $34.42M↓ | $34.99M↓ | $36.38M |
| Operating Income | $3.17M↓ | $6.83M↓ | $8.27M↓ | $10.77M↑ | $9.69M |
| Net Income | $2.28M↑ | $1.95M↓ | $8.19M↑ | $3.19M↓ | $13.72M |
Peer Comparison
JNJUNHPFE
Fundamentals
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormona...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$77.51M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.82%
Volume
Today's trading volume
713,145
Recent News
How The Evolving Story For biote (BTMD) May Shape Future Investor Expectations
The latest analyst update for biote keeps the existing price targets unchanged, signaling no revisions to where the stock is currently pegged by coverage. Even without new target moves, the story around biote does not stand still, and investors still have information to track. Ahead, you will see how to monitor shifts in the narrative so you can stay on top of what matters as new data and opinions emerge. Analyst Price Targets don't always capture the full story. Head over to our Company...
biote Corp. Q1 2026 Earnings Call Summary
Moby summary of biote Corp.'s Q1 2026 earnings call
biote Q1 Earnings Call Highlights
biote (NASDAQ:BTMD) executives said a voluntary recall of certain bioidentical hormone pellet inventory created a temporary but meaningful headwind in the company’s first quarter of 2026, impacting procedure revenue, margins, and salesforce productivity while management works to restore supply conti
biote Corp. (BTMD) Q1 Earnings and Revenues Lag Estimates
biote Corp. (BTMD) delivered earnings and revenue surprises of -33.33% and -2.71%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How The biote (BTMD) Narrative Is Shifting As Targets Tighten And Guidance Holds
Biote’s fair value estimate has been trimmed from US$3.17 to US$2.97 per share, signaling a tighter view on what analysts currently think the stock is worth. That change lines up with recent commentary, where many analysts are lowering price targets into a US$2 to US$3 range while balancing recall related challenges against progress on sales execution and clinic growth efforts. Read on to see how these shifting targets fit into the broader biote story and what to watch as the narrative...